Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors

NCT02508441 | Terminated Phase 1

• 1 other identifier: AB1537-001
• Study Type: interventional
• Target: 22
• Locations: 1 country
• Sites: 1

Brief Summary

This is a first-in-human, open-label, dose escalation and expansion, 2-part study to determine the safety, tolerability, and maximum tolerated dose of Andes-1537 for Injection in patients with advanced unresectable solid tumors that are refractory to standard therapy or for which no standard therapy is available.

Conditions

Advanced Unresectable Solid Tumors

Keywords

Neoplasms; Solid Tumors; Advanced Malignancy; Cancer

Outcome Measures

Primary Outcomes (1)

• Incidence of dose-limiting toxicities

  Determine maximum tolerated dose

  First 4-week treatment cycle

Secondary Outcomes (9)

• Adverse events

  Safety evaluations will be measured through 28 days after last dose of Andes-1537

• Safety laboratory tests

  Safety evaluations will be measured through 28 days after last dose of Andes-1537

• Physical examinations

  Safety evaluations will be measured through 28 days after last dose of Andes-1537

• Vital signs

  Safety evaluations will be measured through 28 days after last dose of Andes-1537

• 12-lead electrocardiogram (ECG)

  First 4-week treatment cycle

Study Arms (1)

Andes-1537 for Injection

EXPERIMENTAL

Part 1 is an open-label, dose-escalation study. Part 2 is an open-label, dose-expansion study.

Drug: Andes-1537 for Injection

Interventions

Andes-1537 for Injection DRUG

Part 1: Andes-1537 subcutaneous injection, 100 to 1000 mg twice a week per 4-week cycle Part 2: Andes-1537 subcutaneous injection, recommended phase 2 dose administered twice a week per 4-week cycle

Andes-1537 for Injection

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Men and women 18 years of age or older
• Can understand and voluntarily sign an informed consent form prior to any study-related assessments or procedures, and are able to adhere to the study visit schedule and other protocol requirements
• Patient with documented pathological evidence of a cancer from which has developed advanced unresectable solid tumors that are, in the opinion of their treating physician, refractory to standard therapy or for which no standard therapy is available
• Consent to tumor biopsy from accessible tissue (optional in Part 1 and mandatory in Part 2)
• Have measureable disease by RECIST
• Have Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
• Have adequate organ function, confirmed by the following laboratory values obtained ≤ 3 days prior to the first treatment: absolute neutrophil count ≥ 1.5 × 10\^9/L; hemoglobin ≥ 9 g/dL; platelets ≥ 100 × 10\^9/L; aspartate transaminase and alanine transaminase ≤ 2.5 × upper limit of normal (ULN); serum total bilirubin ≤ 2.0 × ULN; serum creatinine ≤ 1.5 × ULN, or estimated or measured creatinine clearance ≥ 60 mL/min; prothrombin time, activated partial thromboplastin time ≤ 1.5 × ULN if not on anticoagulation therapy
• Female patients of childbearing potential must have a negative serum pregnancy test and be using adequate contraception prior to study entry and must agree to use adequate contraception from study entry through at least 6 months after discontinuation of study drug.
• Male patients at screening must agree to practice adequate contraception from study entry through at least 6 months after discontinuation of study drug.

You may not qualify if:

• Have symptomatic central nervous system metastases. Patients with brain metastases that have been previously treated and are stable for ≥ 4 weeks or treated with gamma knife surgery and are stable for ≥ 2 weeks are allowed to enter the study.
• Have unstable angina, clinically significant cardiac arrhythmia, New York Heart Association Class 3 or 4 congestive heart failure, or prolonged QT interval corrected wave of greater than 470 ms.
• Receiving treatment with any medication known to produce QT prolongation within 7 days of study entry
• Have had prior systemic chemotherapy treatments or investigational modalities ≤ 5 half-lives or 4 weeks, whichever is shorter, prior to starting treatment with Andes-1537 or who have not recovered from side effects, grade 2 or greater, of such therapy (except alopecia)
• Have had major surgery ≤ 2 weeks prior to starting treatment with Andes-1537 or who have not recovered from side effects of such surgery
• Are pregnant or breastfeeding
• Have had DVT or venous thromboembolism within 6 weeks of study entry
• Have active uncontrolled bleeding or a known bleeding disorder
• Have any serious or unstable concomitant systemic conditions that are incompatible with this clinical study, including but not limited to substance abuse, psychiatric disturbance, or uncontrolled intercurrent illness (including active infection), arterial thrombosis, or symptomatic pulmonary embolism
• Have a known sensitivity to any of the components of Andes-1537
• Are unable or unwilling to follow protocol instructions and requirements

Sponsors & Collaborators

• Andes Biotechnologies: lead

Study Sites (1)

UCSF Medical Center at Mount Zion, Helen Diller Family Comprehensive Cancer Center, Early Phase Clinical Trials

San Francisco, California, 94115, United States

Location

MeSH Terms

Conditions

Neoplasms

Interventions

Injections

Intervention Hierarchy (Ancestors)

Drug Administration Routes; Drug Therapy; Therapeutics

Study Officials

• Pamela Munster, MD

  University of California, San Francisco

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 15, 2015
• First Posted: July 27, 2015
• Study Start: December 8, 2015
• Primary Completion: November 13, 2017
• Study Completion: November 13, 2017
• Last Updated: October 18, 2018

Record last verified: 2018-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)